Page 605 - Read Online

Ralph et al. J Cancer Metastasis Treat 2018;4:49 I http://dx.doi.org/10.20517/2394-4722.2018.42 Page 25 of 26

Downs LS, Nagel CI, Boggess JF, Pearl ML, Ioffe OB, Park KJ, Ali S, Brinton LA. Nonsteroidal anti-inflammatory drugs and endometrial
carcinoma mortality and recurrence. J Natl Cancer Inst 2017;109:1-10.
132. Verdoodt F, Kjaer SK, Friis S. Influence of aspirin and non-aspirin NSAID use on ovarian and endometrial cancer: summary of
epidemiologic evidence of cancer risk and prognosis. Maturitas 2017;100:1-7.
133. Gurpinar E, Grizzle WE, Piazza GA. NSAIDs inhibit tumorigenesis, but how? Clin Cancer Res 2014;20:1104-13.
134. Panieri E, Santoro MM. ROS homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis 2016;7:e2253.
135. Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology. Cell 2017;168:657-69.
136. Liu J, Wang Z. Increased oxidative stress as a selective anticancer therapy. Oxid Med Cell Longev 2015;2015:294303.
137. Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Thomas SP, Gajra A, Bertino E, Reckamp KL, Molina J, Schiller JH,
Mitchell-Richards K, Friedman PN, Ritter J, Milne G, Hahn OM, Stinchcombe TE, Vokes EE; Alliance for Clinical Trials in Oncology.
Phase III randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard chemotherapy for advanced non-small-cell
lung cancer with cyclooxygenase-2 overexpression: CALGB 30801 (Alliance). J Clin Oncol 2017;35:2184-92.
138. Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann
TJ, van den Borne BE, Schramel FM. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and
cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol
2011;29:4320-6.
139. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT, Dannenberg AJ. Celecoxib inhibits prostate
cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005;11:1999-2007.
140. Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN. Celecoxib prevents tumor growth in vivo without toxicity to normal gut:
lack of correlation between in vitro and in vivo models. Cancer Res 2000;60:6045-51.
141. Xu B, Wang Y, Yang J, Zhang Z, Zhang Y, Du H. Celecoxib induces apoptosis but up-regulates VEGF via endoplasmic reticulum stress in
human colorectal cancer in vitro and in vivo. Cancer Chemother Pharmacol 2016;77:797-806.
142. Sobolewski C, Rhim J, Legrand N, Muller F, Cerella C, Mack F, Chateauvieux S, Kim JG, Yoon AY, Kim KW, Dicato M, Diederich M.
2,5-Dimethyl-celecoxib inhibits cell cycle progression and induces apoptosis in human leukemia cells. J Pharmacol Exp Ther 2015;355:308-
28.
143. Schönthal AH. Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications
for glioma therapy. Neurosurg Focus 2006;20:E21.
144. Pyrko P, Kardosh A, Liu YT, Soriano N, Xiong W, Chow RH, Uddin J, Petasis NA, Mircheff AK, Farley RA, Louie SG, Chen TC,
Schönthal AH. Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib,
a non-coxib analogue of celecoxib. Mol Cancer Ther 2007;6:1262-75.
145. Schiffmann S, Maier TJ, Wobst I, Janssen A, Corban-Wilhelm H, Angioni C, Geisslinger G, Grösch S. The anti-proliferative potency of
celecoxib is not a class effect of coxibs. Biochem Pharmacol 2008;76:179-87.
146. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase
(COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 2002;62:2029-33.
147. Jendrossek V, Handrick R, Belka C. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J 2003;17:1547-9.
148. Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a
new class of apoptosis-inducing agents. J Natl Cancer Inst 2002;94:1745-57.
149. Bosch R, Dieguez-Gonzalez R, Céspedes MV, Parreño M, Pavón MÁ, Grañena A, Sierra J, Mangues R, Casanova I. A novel inhibitor of
focal adhesion signaling induces caspase-independent cell death in diffuse large B-cell lymphoma. Blood 2011;118:4411-20.
150. Casanova I, Bosch R, Lasa A, Parreño M, Céspedes MV, Brunet S, Nomdedéu JF, Mangues MA, Sierra J, Mangues R. A celecoxib
derivative inhibits focal adhesion signaling and induces caspase-8-dependent apoptosis in human acute myeloid leukemia cells. Int J Cancer
2008;123:217-26.
151. Bosch R, Moreno MJ, Dieguez-Gonzalez R, Céspedes MV, Gallardo A, Trias M, Grañena A, Sierra J, Casanova I, Mangues R. A novel
orally available inhibitor of focal adhesion signaling increases survival in a xenograft model of diffuse large B-cell lymphoma with central
nervous system involvement. Haematologica 2013;98:1242-9.
152. Ralph SJ, Pritchard R, Rodríguez-Enríquez S, Moreno-Sánchez R, Ralph RK. Hitting the bull’s-eye in metastatic cancers-NSAIDs elevate
ROS in mitochondria, inducing malignant cell death. Pharmaceuticals (Basel) 2015;8:62-106.
153. Pritchard R, Rodríguez-Enríquez S, Pacheco-Velázquez SC, Bortnik V, Moreno-Sánchez R, Ralph S. Celecoxib inhibits mitochondrial O2
consumption, promoting ROS dependent death of murine and human metastatic cancer cells via the apoptotic signalling pathway. Biochem
Pharmacol 2018;154:318-34.
154. Pacheco-Velázquez SC, Robledo-Cadena DX, Hernández-Reséndiz I, Gallardo-Pérez JC, Moreno-Sánchez R, Rodríguez-Enríquez S.
Energy metabolism drugs block triple negative breast metastatic cancer cell phenotype. Mol Pharm 2018;15:2151-64.
155. Huang C, Chen Y, Liu H, Yang J, Song X, Zhao J, He N, Zhou CJ, Wang Y, Huang C, Dong Q. Celecoxib targets breast cancer stem cells by
inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity. Oncotarget 2017;8:115254-69.
156.Kurtova AV, Xiao J, Mo Q, Pazhanisamy S, Krasnow R, Lerner SP, Chen F, Roh TT, Lay E, Ho PL, Chan KS. Blocking PGE2-induced
tumour repopulation abrogates bladder cancer chemoresistance. Nature 2015;517:209-13.
157. Wang JS, Ho FM, Kang HC, Lin WW, Huang KC. Celecoxib induces heme oxygenase-1 expression in macrophages and vascular smooth
muscle cells via ROS-dependent signaling pathway. Naunyn Schmiedebergs Arch Pharmacol 2011;383:159-68.
158. Hamdulay SS, Wang B, Birdsey GM, Ali F, Dumont O, Evans PC, Haskard DO, Wheeler-Jones CP, Mason JC. Celecoxib activates PI-3K/
Akt and mitochondrial redox signaling to enhance heme oxygenase-1-mediated anti-inflammatory activity in vascular endothelium. Free
Radic Biol Med 2010;48:1013-23.
159. Al-Rashed F, Calay D, Lang M, Thornton CC, Bauer A, Kiprianos A, Haskard DO, Seneviratne A, Boyle JJ, Schönthal AH, Wheeler-Jones
CP, Mason JC. Celecoxib exerts protective effects in the vascular endothelium via COX-2-independent activation of AMPK-CREB-Nrf2